NEW

Sony Expands Lineup of 4K Medical Monitors

Sony’s latest 4K LCD display, the LMD-X3200MD, is a multi-functional 32-inch medical monitor ideal for use in hospital operating rooms, surgical centers and clinics. It combines high picture quality, installation flexibility and ease of use, with advanced features...

Residual Disinfection in the Operating Room

By Katherine Velez As the COVID-19 pandemic continues, health care facilities face mounting pressure to elevate surface disinfection practices. Although AORN guidelines do not specifically address residual disinfection products, because of the heightened focus on...

Getinge Expands Vascular Surgery Business

Getinge is investing 3 million Euros in its manufacturing of polyester grafts and patches to treat aneurysmal and occlusive diseases. The investment aims at increasing manufacturing capacity in Getinge’s site in La Ciotat, France. Getinge has more than 50 years of...

STERIS Acquires Key Surgical

STERIS plc has signed a definitive agreement to purchase Key Surgical, a portfolio company of Water Street Healthcare Partners LLC, through a U.S. subsidiary for $850 million. STERIS anticipates that the acquisition will qualify for a tax benefit related to tax...

Ultrapotent compound may help treat C. diff, reduce recurrence

Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry, has helped advance novel compounds to help treat patients with C. diff.

Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S.

Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. diff, but even these therapies suffer from high treatment failure and recurrence.

Now, Purdue University innovators have advanced novel compounds that they developed to help treat patients with C. diff, one of only four bacteria considered an urgent threat by the Centers for Disease Control and Prevention. Their work is published in the Journal of Medicinal Chemistry.

“Our compounds have several advantages, including ultrapotent activities with minimum inhibitory concentration values as low as 0.003 μg/mL,” said Herman O. Sintim, the Drug Discovery Professor of Chemistry in Purdue’s Department of Chemistry. “Our compounds also do not kill good bacteria at concentrations that kill C. diff and performed significantly better than current antibiotics in preventing recurrence. These are significant advantages for patients dealing with this difficult bacterial infection.”

The most promising of the Purdue compounds, containing trifluoromethylthio functional group, is HSGN-218. Sintim said it has been shown to be one of the most potent compounds ever produced for use against C. diff.

“This is part of our work to create new solutions to treat diseases and infections that are resistant to current treatment options,” said Sintim, who is a member of the Purdue University Center for Cancer Research and the Purdue Institute for Drug Discovery. “This work provides a potential clinical lead for the development of C. diff therapeutics and also highlights dramatic drug potency enhancement via halogen substitution.”

The researchers patented their compounds through the Purdue Research Foundation Office of Technology Commercialization, which is looking for partners to advance the technology. For more information, contact Joseph Kasper at OTC at jrkasper@prf.org and mention track code 2019-SINT-68535.

George Naclerio, a researcher on Sintim’s team, has been awarded a National Institutes of Health T32 training grant to help facilitate the development of this technology.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X